|
|
303 George St., Suite 420
New Brunswick, NJ 08901 United States
phone:(732) 296-8400
fax:732-296-9292
|
|
| Symbol |
SNT |
| Exchange |
AMEX |
| Founded |
1999 |
| Employees |
5 |
|
|
| www.senesco.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Proprietary gene-based technology for use in human therapeutic and agricultural applications. |
|
| Management |
| Harlan Waksal, M.D., Chairman; Jack van Hulst, CEO; John Thompson, Ph.D., Executive VP of R&D and CSO; Joel Brooks, CFO; Sascha Fedyszyn, VP of Corporate Development; Richard Dondero, VP of R&D. |
| |
|
|
|
|
|
|
|
| Keywords |
| genomics, cancer, glaucoma, heart disease, SNT |
|
|
|
| Description |
|
Senesco Technologies is a U.S. biotechnology company, developing its proprietary
eiF5A (Factor 5A) gene technology as a potential treatment for both oncology and
inflammatory conditions. Senesco's platform technology is based upon the identification
and characterization of specific genes that regulate cell death in plants (senescence)
and humans (apoptosis), and then utilizing this information for therapeutic purposes.
Cumulatively, Senesco�s mission is to apply its technology to improve commercial
agriculture and to develop treatments for medical conditions in humans. |
|
| Products / Services |
Senesco has designed a drug called SNS-01 that is specifically targeted to multiple myeloma, its first clinical target. SNS-01 contains three parts: a DNA plasmid which increases the lysine form of Factor 5A thereby causing death of the cancer cells; an siRNA against the hypusine form of Factor 5A thereby reducing inflammation; and a PEI nanoparticle that protects the plasmid and siRNA combination therapy while delivering it to cancer cells.
|
|
| Technology / Differentiation |
| Senesco's proprietary technology is based on a gene called Factor 5A. Factor 5A has two forms, the lysine and hypusine forms, which act in concert as a regulatory switch. If the lysine form of Factor 5A is over expressed relative to the hypusine form, the switch is turned on and cell death occurs. Conversely if the hypusine form is at higher levels then the switch is off and the cell survives. |
|
|
| Status |
| Preclinical testing of SNS-01. Senesco's near term objectives are finalization of the formulation of SNS-01, a definitive toxicity study in larger animals to ensure safety and the approval of the Investigational New Drug application by the FDA, which should then lead to commencement of the trial at Mayo Clinic. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
